B7-1/CD80 Antibody (IDEC-114 (Galiximab)) [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-81100CL1
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Block/Neutralize, ELISA, Flow Cytometry, Functional, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
Label
CoraFluor 1
Antibody Source
Recombinant Monoclonal Rabbit IgG Lambda Clone # IDEC-114 (Galiximab)
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Galiximab was prepared by immunizing cynomolgus monkeys with recombinant B7-1/CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)
Specificity
Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to B7-1/CD80. B7-1/CD80 is a surface glycoprotein and a member of the B7 family of costimulatory molecules. B7-1/CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed consitutively on various subtypes of B-cell lymphomas.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Lambda
Description
CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
Applications for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) [CoraFluor™ 1]
Application
Recommended Usage
Block/Neutralize
Optimal dilutions of this antibody should be experimentally determined.
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunoprecipitation
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark. Do not freeze.
Background: B7-1/CD80
Alternate Names
B71, CD80
Gene Symbol
CD80
Additional B7-1/CD80 Products
Product Documents for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) [CoraFluor™ 1]
Product Specific Notices for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) [CoraFluor™ 1]
CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...